POLB - POOLBEG PHARMA - Share Chat
Poolbeg Pharma (AIM: POLB) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for infectious diseases. Operating with a ‘capital light’ model, the company aims to acquire and repurpose de-risked late-stage clinical assets, advancing them to key value inflection points before out-licensing to larger pharmaceutical partners.
Spun out from Amryt Pharma, Poolbeg leverages a proprietary AI-powered drug discovery platform to identify and accelerate drug candidates, particularly for their potential in mitigating severe inflammatory responses, or hypercytokinaemia, associated with infections. Its pipeline includes programmes targeting influenza (POLB 001), Respiratory Syncytial Virus (RSV), and a p38 MAP Kinase inhibitor for severe influenza. The company’s strategy focuses on addressing areas of significant unmet medical need while efficiently managing R&D expenditure.
Chat about POOLBEG PHARMA
Poolbeg Pharma (POLB) – quite a year so far! With the positive POLB 001 data and that US Orphan Drug Designation for POLB 002, they're making waves. What's your take on their AI-driven strategy and the potential for these early-stage assets? Are we looking at a long-term hold or a speculative play? Thoughts on their valuation?